Cat. No. 2797
Chemical Name: 5-Methyl-4-[(1R,6R)-3-methyl-6-(1-c
Biological ActivityAnalog of cannabidiol that is a potent agonist at the GPR55 cannabinoid receptor (EC50 values are 13, > 30000 and > 30000 nM for GPR55, CB1 and CB2 receptors respectively). Induces activation of RhoA, cdc42 and rac1.
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
Certificate of Analysis / Safety Data Sheet
Johns et al (2007) The novel endocannabinoid receptor GPR55 is activated by atypical cannabinoids but does not mediate their vasodilator effects. Br.J.Pharmacol. 152 825. PMID: 17704827.
Ryberg et al (2007) The orphan receptor GPR55 is a novel cannabinoid receptor. Br.J.Pharmacol. 152 1092. PMID: 17876302.
If you know of a relevant reference for this product please let us know.
Citations are publications that use Tocris products. Selected citations for O-1602 include:
Ailte et al (2016) Addition of lysophospholipids with large head groups to cells inhibits Shiga toxin binding Scientific Reports 6 30336. PMID: 27458147.
Romero-Zerbo et al (2011) A role for the putative cannabinoid receptor GPR55 in the islets of Langerhans. J Endocrinol 211 177. PMID: 21885477.
Schicho et al (2011) The atypical cannabinoid O-1602 protects against experimental colitis and inhibits neutrophil recruitment. Inflamm Bowel Dis 17 1651. PMID: 21744421.
Daly et al (2010) Fluorescent ligand binding reveals heterogeneous distribution of adrenoceptors and 'cannabinoid-like' receptors in small arteries. Br J Pharmacol 159 787. PMID: 20136833.
View Related Products by Target
View Related Products by Product Action
Keywords: O-1602, supplier, Potent, GPR55, receptor, agonists, cannabinoids, Receptors, 0-1602, Tocris Bioscience, GPR55 Agonist products